Hyperpigmentation

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Retrieved on: 
Wednesday, March 6, 2024
Lentigo, Pigment, Metabolism, Melasma, Elasticity, UVR, Ageing, Patent, Phio Pharmaceuticals, Skin, Hyperpigmentation, Gene silencing, TYR, Downregulation and upregulation, Iodosobenzene, MMP1, Vaccine

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.

Key Points: 
  • The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.
  • Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis.
  • “We have a robust patent portfolio for Phio’s INTASYL siRNA technology,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
  • “The addition of this recent patent grant for treatment of photodamaged skin is complementary to our current initiative in treating skin cancer.”

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, February 22, 2024
EMANATE, New Drug Application, Investment, Obesity, BMI, Webcast, Initiate, BBS, Stage 2, Hyperpigmentation, Documentation, Polyphagia, European, GAAP, European Medicines Agency, PCSK1, Type, Type 2, G&A, LG Chem, BV, Completeness, Shanda, Bardet–Biedl syndrome, Clinical trial, LEPR, Medicaid, IND, Prescription, Research, Hunger, Acquisition, Quarter, EMA, MC4R, FDA, Prevalence, PMDA, Patient, POMC, Body mass index, Pharmaceutical industry

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points: 
  • ET --
    BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
  • S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
  • ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals, a Subsidiary of Waldencast plc.

Retrieved on: 
Tuesday, February 20, 2024
Acne, WALD, Physician, Dermabrasion, Growth, Dermatology, Surgeon, Hyperpigmentation, Gold, Health, Patient, Laser, Pharmaceutical industry

Obagi is a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform and publicly listed company.

Key Points: 
  • Obagi is a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform and publicly listed company.
  • Dr. Suzan Obagi is a world-renowned, leading board-certified dermatologist and cosmetic surgeon, recognized for her groundbreaking contributions to the fields of dermatology, cosmetic surgery, and skincare.
  • “I am thrilled to be taking on a more formal role at Obagi as the Company’s first-ever Chief Medical Director,” said Dr. Suzan Obagi.
  • "We are honored to deepen our relationship with Dr. Suzan Obagi as she assumes the role of Obagi’s inaugural Chief Medical Director," said Jordan Meyer, President of Obagi.

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
Thursday, February 22, 2024
Health, Other Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Therapy, Skin cancer, Neoplasm, Recurrence, Melasma, Scar, Toxicity, Melanocyte, FDA, SKS, Skin, Dermatoscopy, BCC, Entrepreneurship, Hyperpigmentation, Risk, Epidermis, Safety, PLA, Patient, Carcinoma, Laser, Medical imaging

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

COSRX Returns to TikTok with the #PatThePeptide Campaign, Highlighting the Accessibility of Peptide Skincare

Retrieved on: 
Thursday, March 7, 2024
Cream, Collection, Absorption, Skin, Hyperpigmentation, Peptide, Vitamin C, Vitamin, Serum, Vaccine

The #PatThePeptide campaign aims to showcase and emphasize how COSRX's popular product, The 6 Peptide Skin Booster Serum , has made skincare more accessible than ever.

Key Points: 
  • The #PatThePeptide campaign aims to showcase and emphasize how COSRX's popular product, The 6 Peptide Skin Booster Serum , has made skincare more accessible than ever.
  • Easy Derm Skincare: The serum seamlessly integrates into all skincare routines, offering comfort and ease of use without fear of irritation.
  • Skincare for All: COSRX products are clinically verified, hypoallergenic, and suitable for all skin types, including sensitive skin.
  • Additionally, the top 90 winners will receive The 6 Peptide Skin Booster Serum and a randomly selected COSRX product from COSRX's collection.

Defense Blends Icon Age Defense Face Moisturizer Wins The HisHealthMag 2024 Award for the Cleanest, Most Effective Anti-Aging Men's Moisturizer

Retrieved on: 
Thursday, March 7, 2024
Q10, Dry, Ageing, Defense, Skin, Hyperpigmentation, Hyaluronic acid, Allergy, Oil, Antioxidant, Irritation, Cosmetics

NEW YORK, March 7, 2024 /PRNewswire/ -- In the emerging market of men's skincare products, Defense Blends has garnered attention as an effective option for men seeking to combat visible signs of aging. Recognizing the brand's excellence, HisHealthMag has named Defense Blends Icon Age Defense Face Moisturizer as the cleanest and most effective anti-aging men's moisturizer. [See full press release.]

Key Points: 
  • HisHealthMag has chosen Defense Blends Icon Age Defense Face Moisturizer as the cleanest, most effective anti-aging men's moisturizer, recognizing the product's excellence in men's skincare.
  • NEW YORK, March 7, 2024 /PRNewswire/ -- In the emerging market of men's skincare products, Defense Blends has garnered attention as an effective option for men seeking to combat visible signs of aging.
  • Recognizing the brand's excellence, HisHealthMag has named Defense Blends Icon Age Defense Face Moisturizer as the cleanest and most effective anti-aging men's moisturizer.
  • Their Icon Age Defense Face Moisturizer epitomizes the brand's commitment to gentle yet effective skincare.

Innovative Hyperpigmentation Solutions: Insights from Our Latest Research

Retrieved on: 
Thursday, February 22, 2024
Pigment, JDD, Hyperpigmentation, Journal

In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.

Key Points: 
  • In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.
  • The latest publication in the Journal of Drugs in Dermatology (JDD), February 2024 issue, presents a groundbreaking study that could change the paradigm in the field of hyperpigmentation solutions.
  • The study, led by a team of distinguished pigmentation experts across the globe, introduces a novel dermatological approach that promises equal efficacy to the gold standard with a rapid onset of action and enhanced patient satisfaction.

Innovative Hyperpigmentation Solutions: Insights from Our Latest Research

Retrieved on: 
Thursday, February 22, 2024
Pigment, JDD, Hyperpigmentation, Journal

In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.

Key Points: 
  • In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.
  • The latest publication in the Journal of Drugs in Dermatology (JDD), February 2024 issue, presents a groundbreaking study that could change the paradigm in the field of hyperpigmentation solutions.
  • The study, led by a team of distinguished pigmentation experts across the globe, introduces a novel dermatological approach that promises equal efficacy to the gold standard with a rapid onset of action and enhanced patient satisfaction.

COSRX Celebrates the Return of The 6 Peptide Skin Booster Serum - A Derm-Favorite Now Back in Stock at Ulta

Retrieved on: 
Friday, February 16, 2024
Cream, Gland, Peptide, Vitamin, Skin, Serum, Hyperpigmentation, Cosmetics

LOS ANGELES, Feb. 16, 2024 /PRNewswire/ -- COSRX, the beloved beauty brand known for its derm-favourite skincare solutions, is delighted to announce the return of the COSRX The 6 Peptide Skin Booster Serum at Ulta.

Key Points: 
  • LOS ANGELES, Feb. 16, 2024 /PRNewswire/ -- COSRX, the beloved beauty brand known for its derm-favourite skincare solutions, is delighted to announce the return of the COSRX The 6 Peptide Skin Booster Serum at Ulta.
  • The exceptional popularity of The 6 Peptide Skin Booster Serum can be attributed to its unique blend of six peptides which works wonders in addressing various skin concerns, making it the go-to solution for anyone seeking perfect skin.
  • COSRX recommends incorporating The 6 Peptide Skin Booster Serum as the first step of one's skincare routine.
  • "We are delighted to bring back The 6 Peptide Skin Booster Serum to Ulta after its remarkable success," said a spokesperson for COSRX.

VI Peel® Announces 36% Boost in Anti-Aging Benefits of Botox® from New Clinical Study

Retrieved on: 
Tuesday, February 13, 2024
Pain, Acne, Melasma, ALL, RN, Patient satisfaction, Ageing, JDD, Skin, MBA, Hyperpigmentation, Habit, Patient, Smash Mouth, FAAD, Trial of the century, Cosmetics

"The efficacy of VI Peel and Botox same-day treatment was clinically proven by the improvements to wrinkle severity, uniformity of pigment, and skin tone via photographic matching," Roberts says.

Key Points: 
  • "The efficacy of VI Peel and Botox same-day treatment was clinically proven by the improvements to wrinkle severity, uniformity of pigment, and skin tone via photographic matching," Roberts says.
  • "The clinical significance of this combination will appeal to multi-generational patients where anti-aging and skin health remain at the forefront of their buying habits."
  • This is in direct contrast to the majority of medical or clinical studies that favor Caucasians or lighter Fitzpatrick types.
  • A ToxBooster Treatment combines a VI Peel followed immediately by a Neurotoxin Injection (like Botox®, Xeomin®, Dysport®, Juveau® and Daxxify®).